Background: Murepavadin (POL7080) represents the first member of a novel class of outer membrane proteintargeting antibiotics. Murepavadin acts by binding to LPS transport protein D and is being developed for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Introduction
Murepavadin (formerly POL7080) is a 14-amino-acid cyclic peptide for intravenous administration that represents the first member of a novel class of outer membrane protein-targeting antibiotics. 1 It acts by binding to LPS transport protein D (LptD), an essential protein in the outer membrane of the bacterium, blocks the LPS translocation and ultimately kills the bacterium. [2] [3] [4] [5] The most clear documentation on the essentiality of LptD for growth in Pseudomonas aeruginosa PA01 was investigated using conditional mutants employing a rhamnose-inducible promoter. 5 In these experiments the authors showed that cells were only viable when rhamnose was present in the medium, demonstrating the need for LptD expression for growth. In a second study, Balibar and Grabowicz 3 engineered mutants of LptD and determined that certain mutations (specifically deletions in alpha-helical loop L4 situated on the extracellular surface of the protein) led to a generalized permeabilization of P. aeruginosa, but mutations in the central core of the protein were found to be non-viable, again supporting the essential nature of the protein. Thus, given the pathogen-specific nature of murepavadin, it is unlikely to generate resistance or negatively impact the patient's native bacterial flora, which are both unintended sequelae of treatment with broadspectrum antibiotics. This novel agent is in Phase 3 development for the treatment of nosocomial pneumonia suspected or known to be caused by P. aeruginosa (https://clinicaltrials.gov/ct2/show/ NCT03409679? cond"murepavadin&rank"1).
P. aeruginosa is an important pathogen frequently implicated in healthcare-associated infections, particularly in critically ill or immunocompromised patients. P. aeruginosa is the second leading cause of hospital-acquired pneumonia and ventilator-associated pneumonia and one of the major causes of healthcare-associated bloodstream infections, urinary tract infections and skin and skin structure infections. 6 The increasing prevalence of MDR and XDR strains is a cause of great concern as it makes the selection of appropriate empirical and definitive antimicrobial treatments very difficult. [7] [8] [9] Previously, murepavadin was shown to display potent activity against P. aeruginosa including a small subset of XDR isolates. 10 In order to better define the activity of murepavadin against XDR P. aeruginosa, in this study we evaluated the in vitro activity of murepavadin and comparator agents against a very large panel of contemporary clinical isolates of XDR P. aeruginosa.
Materials and methods
Organisms tested originated from the SENTRY Antimicrobial Surveillance Program. Bacterial isolates were consecutively collected from medical centres according to the site of infection. Only one isolate per patient episode was included in the study. Isolate identity was confirmed at the species level by the monitoring reference laboratory (JMI Laboratories, North Liberty, Iowa, USA). The isolates were collected from 34 medical centres in 21 European nations (n " 353) and 75 medical centres in North America (n " 432), including 73 centres in the USA (n " 426) and 2 in Canada (n " 6).
Isolates were collected mainly from patients hospitalized with pneumonia (63%), skin and soft tissue infections (19%) and bloodstream infections (10%) and categorized as XDR according to criteria published by Magiorakos et al., 11 defining XDR as non-susceptible to 1 agent in all but 2 antimicrobial classes. The antimicrobial classes and drug representatives used in the analysis were: antipseudomonal cephalosporins (ceftazidime and cefepime), carbapenems (imipenem, meropenem and doripenem), broad-spectrum penicillins combined with a b-lactamase inhibitor (piperacillin/tazobactam), fluoroquinolones (ciprofloxacin and levofloxacin), aminoglycosides (gentamicin, tobramycin and amikacin) and the polymyxins (colistin).
Isolates were tested against murepavadin and comparator agents by the reference broth microdilution method (CLSI M07, 2018) 12 using CAMHB. CLSI (CLSI M100, 2018) 13 and EUCAST 14 interpretive criteria were used to determine susceptibility/resistance rates for comparator agents. Quality control was tested daily and inoculum density was monitored by colony counts. The quality control strains were P. aeruginosa ATCC 27853 and PA3140.
Results
Murepavadin (MIC 50/90 , 0.12/0.25 mg/L) was the most active agent and inhibited 98.7% of isolates at 2 mg/L (Table 1) . Based on MIC 50/90 values, murepavadin was 8-fold more potent than colistin (MIC 50/90 , 1/2 mg/L) against this collection of XDR P. aeruginosa (Table 1) Table 1 ).
Only seven isolates (0.9%) exhibited murepavadin MIC values .4 mg/L (Table 1) , six isolates from the USA and one from Europe (Ireland). The US isolates with elevated murepavadin MIC values (.4 mg/L) were from California (three isolates from two medical centres), Illinois (one isolate), New Mexico (one isolate) and New York (one isolate). All seven isolates were susceptible to colistin, three of the isolates were non-susceptible to ceftolozane/tazobactam and only one isolate was resistant to meropenem. The mechanism of elevated MICs of murepavadin for these strains is under investigation, but previous results have shown that mutations in the periplasmic domain of LptD can lead to elevated MICs of murepavadin. 4, 15 Among the comparator agents tested, colistin was the most active compound (MIC 50/90 , 1/2 mg/L; 93.6% susceptible), followed by ceftolozane/tazobactam (MIC 50/90 , 2/>32 mg/L; 70.6% susceptible), tobramycin (MIC 50/90 , 8/>8 mg/L; 47.5% susceptible) and amikacin [MIC 50/90 , 16/>32 mg/L; 45.5%/61.6% susceptible (EUCAST/CLSI); Table 2 ]. Susceptibility rates (EUCAST and CLSI criteria) for meropenem, piperacillin/tazobactam and ceftazidime were 5.6%, 7.3% and 20.0%, respectively; and only 2.3%/6.9% of isolates were susceptible to levofloxacin according to EUCAST/CLSI criteria ( Table 2) .
Murepavadin activity against isolates from Europe (MIC 50/90 , 0.12/0.25 mg/L) was very similar to the agent's activity against isolates from North America (MIC 50/90 , 0.12/0.5 mg/L; Tables 1 and 2 ). In contrast, susceptibility rates for ceftolozane/tazobactam, amikacin and tobramycin were substantially lower among XDR P. aeruginosa from Europe (50.7%, 39.5% and 23.5% per CLSI, respectively) compared with North America (86.8%, 79.6% and 67.1% per CLSI, respectively; Table 2 ).
Discussion
MDR and XDR P. aeruginosa result from the bacterium's notable inherent antibiotic resistance, in addition to its ability to acquire and Isolates from both geographical regions.
Murepavadin activity against P. aeruginosa JAC harbour diverse resistance determinants. 16, 17 Low outer membrane permeability in combination with multidrug efflux systems account for its intrinsic mechanisms of resistance. Additional resistance mechanisms in P. aeruginosa include enzyme production, outer membrane protein (porin) loss and target mutations. A wide variety of b-lactamases are produced by P. aeruginosa and some of these enzymes can confer resistance to all b-lactams currently available for clinical use, especially when associated with porin loss and/or overexpression of efflux pumps. Furthermore, expression of aminoglycoside-modifying enzymes (acetyltransferases, nucleotidyltransferases and phosphotransferases), mediating aminoglycoside resistance, and mutations in DNA gyrase and Criteria as published by CLSI 13 and EUCAST. 14 Sader et al.
topoisomerase IV that confer resistance to the fluoroquinolones are common in P. aeruginosa.
17
Recently, as part of the implementation of the Global Action Plan on Antimicrobial Resistance, the WHO drew up a list of priority pathogens that included carbapenem-and thirdgeneration cephalosporin-resistant Enterobacteriaceae as well as carbapenem-resistant Acinetobacter baumannii and carbapenemresistant P. aeruginosa as a critical concern. 18 We evaluated a large collection of highly resistant P. aeruginosa isolates collected from 109 medical centres distributed in 96 cities of 23 nations and the results of this investigation indicate that the vast majority of resistance mechanisms commonly found in P. aeruginosa worldwide do not seem to affect murepavadin activity, since it retained potent activity against isolates resistant to b-lactams (including ceftolozane/tazobactam and carbapenems), aminoglycosides (tobramycin and amikacin) and the polymyxin colistin.
Therefore, murepavadin has the potential to treat P. aeruginosa infections where currently there is an unmet medical need. Multiple studies have demonstrated that early introduction of appropriate antimicrobial therapy is the major determinant of clinical outcome in serious P. aeruginosa infections, especially hospitalacquired and ventilator-associated pneumonia. 7, 8, 19 One rational strategy is to initiate therapy with broad-spectrum antimicrobials until full culture and susceptibility results are available and then de-escalate or streamline to the most appropriate patient-specific regimen once the pathogen(s) and susceptibility profile are known; however, narrow-spectrum or pathogen-specific antimicrobial treatment should be introduced as early as possible. 20 The benefits of pathogen-specific antimicrobial treatment include reduced adverse events, such as Clostridium difficile infection, and improvement in rates of antimicrobial resistance. 21 It is also important to note that empirical treatment decisions for suspected P. aeruginosa infections are particularly difficult owing to the increased antimicrobial resistance rates and limited number of antipseudomonal agents available. Recent studies have shown that only the polymyxins, some aminoglycosides (tobramycin and amikacin) and the recently approved b-lactam/b-lactamase inhibitor combinations ceftazidime/avibactam and ceftolozane/tazobactam provide appropriate anti-P. aeruginosa coverage in some geographical regions; however, there still remains a high percentage of carbapenem-resistant P. aeruginosa strains that may be refractory to treatment based on in vitro susceptibility data. 9, 22, 23 This, combined with the new reports on the emergence of resistance to these antibiotics, suggests that new agents with a new mode of action are clearly needed. 24, 25 In summary, the results of this study showed that murepavadin was very active against a large collection of clinical XDR P. aeruginosa isolates from Europe and North America and retained good activity against XDR P. aeruginosa isolates that were non-susceptible to colistin, ceftolozane/tazobactam and/or tobramycin. The very potent and extensive coverage of P. aeruginosa positions this antimicrobial agent well for therapy when there are clinical risk factors associated with MDR P. aeruginosa nosocomial pneumonia. These important features also ensure an appropriate initial antibiotic treatment and reduce the associated mortality when an initial inappropriate antibiotic therapy is prescribed. Furthermore, the pathogen-specific nature of murepavadin is ideal for use in stewardship programmes in which the de-escalation of broad-spectrum agents is warranted after the availability of susceptibility data. The results presented here, coupled with results from ongoing clinical studies, will define the role of murepavadin for treating P. aeruginosa infections, including those caused by XDR isolates.
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